The Product Information (PI) for ibrutinib is being updated to reflect new safety information following reports of ventricular tachyarrhythmia, hepatitis B reactivation and severe opportunistic infections. According to a TGA Medicines Safety Update, the tyrosine kinase inhibitor has been associated with 52 cases of ventricular tachyarrhythmia. “Based on current evidence, the role of ibrutinib in ...
TGA warns of cardiac and infection risk with ibrutinib
23 Nov 2017